Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Melanocytic Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Melanocytic Neoplasm

Cancer Family

Melanocytic Neoplasm

CI-CAN-00000026Explore in graph →

Non-malignant609 active trials13 approved drugs233 evidence items

NCIt: C7058

Overview
Statistics
Survival
Genomics26
Variants & evidence233
Drugs64
Trials3258
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (185)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 126–150 of 185 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

A pediatric case of pigmented epithelioid melanocytoma with chromosomal copy number alterations in 15q and 17q and a novel NTRK3-SCAPER gene fusion.
· J Cutan Pathol · 2020 · PMID 31437301 · validated civic_curation pubmed
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition.
· Cancer Discov · 2014 · PMID 24265152 · validated civic_curation pubmed
Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.
· Nat Genet · 2009 · PMID 19718025 · validated civic_curation pubmed
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
· Cancer Res · 2014 · PMID 25056119 · validated civic_curation pubmed
Overexpression of DDX43 mediates MEK inhibitor resistance through RAS Upregulation in uveal melanoma cells.
· Mol Cancer Ther · 2014 · PMID 24899684 · validated civic_curation pubmed
Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
· Proc Natl Acad Sci U S A · 2013 · PMID 23431193 · validated civic_curation pubmed
Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma.
· Nat Med · 2016 · PMID 27500726 · validated civic_curation pubmed

Showing 126–150 of 185 publications

← Previous
1
…
5
6
7
8
Next →

Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain.

· Pigment Cell Melanoma Res · 2014 · PMID 24112705 · validated civic_curation pubmed

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

· Nature · 2014 · PMID 24670642 · validated civic_curation pubmed

Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations.

· Oncogene · 2014 · PMID 24141786 · validated civic_curation pubmed

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.

· Nature · 2015 · PMID 25970248 · validated civic_curation pubmed

RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models.

· Cancer Res · 2010 · PMID 20551065 · validated civic_curation pubmed

An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation.

· Nat Med · 2016 · PMID 27135738 · validated civic_curation pubmed

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.

· Cancer Discov · 2014 · PMID 24265153 · validated civic_curation pubmed

MEK1 mutations confer resistance to MEK and B-RAF inhibition.

· Proc Natl Acad Sci U S A · 2009 · PMID 19915144 · validated civic_curation pubmed

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.

· Mol Cancer Ther · 2009 · PMID 19671763 · validated civic_curation pubmed

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

· Cancer Res · 2014 · PMID 24576830 · validated civic_curation pubmed

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.

· Clin Cancer Res · 2013 · PMID 23812671 · validated civic_curation pubmed

Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.

· Mol Cancer Ther · 2013 · PMID 23960094 · validated civic_curation pubmed

BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition.

· Clin Cancer Res · 2013 · PMID 24345920 · validated civic_curation pubmed

Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.

· Clin Cancer Res · 2012 · PMID 22038994 · validated civic_curation pubmed

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.

· Pigment Cell Melanoma Res · 2014 · PMID 24495407 · validated civic_curation pubmed

Elucidating distinct roles for NF1 in melanomagenesis.

· Cancer Discov · 2013 · PMID 23171796 · validated civic_curation pubmed

MEK targeting in N-RAS mutated metastatic melanoma.

· Mol Cancer · 2014 · PMID 24588908 · validated civic_curation pubmed

Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib.

· Clin Cancer Res · 2013 · PMID 24132921 · validated civic_curation pubmed